Regarding downregulated pathways identified by RNA-seq (Figure 4A), we hypothesized that downregulation of BCR-related genes induced by ironomycin could potentiate the cytotoxic effect of BCR-inhibiting therapy in MCL. This evidence concerns the gene BCR and mantle cell lymphoma.